Dillon & Associates’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-10,260
| Closed | -$9K | – | 71 |
|
|
2019
Q4 | $9K | Hold |
10,260
| – | – | ﹤0.01% | 68 |
|
|
2019
Q3 | $6K | Hold |
10,260
| – | – | ﹤0.01% | 67 |
|
|
2019
Q2 | $5K | Hold |
10,260
| – | – | ﹤0.01% | 66 |
|
|
2019
Q1 | $5K | Hold |
10,260
| – | – | ﹤0.01% | 66 |
|
|
2018
Q4 | $5K | Hold |
10,260
| – | – | ﹤0.01% | 65 |
|
|
2018
Q3 | $5K | Hold |
10,260
| – | – | ﹤0.01% | 72 |
|
|
2018
Q2 | $5K | Hold |
10,260
| – | – | ﹤0.01% | 69 |
|
|
2018
Q1 | $4K | Hold |
10,260
| – | – | ﹤0.01% | 68 |
|
|
2017
Q4 | $4K | Sell |
10,260
-400
| -4% | -$152 | ﹤0.01% | 67 |
|
|
2017
Q3 | $4K | Hold |
10,660
| – | – | ﹤0.01% | 70 |
|
|
2017
Q2 | $4K | Hold |
10,660
| – | – | ﹤0.01% | 71 |
|
|
2017
Q1 | $5K | Hold |
10,660
| – | – | ﹤0.01% | 73 |
|
|
2016
Q4 | $4K | Hold |
10,660
| – | – | ﹤0.01% | 70 |
|
|
2016
Q3 | $3K | Hold |
10,660
| – | – | ﹤0.01% | 70 |
|
|
2016
Q2 | $3K | Hold |
10,660
| – | – | ﹤0.01% | 70 |
|
|
2016
Q1 | $1K | Hold |
10,660
| – | – | ﹤0.01% | 69 |
|
|
2015
Q4 | $1K | Hold |
10,660
| – | – | ﹤0.01% | 65 |
|
|
2015
Q3 | $2K | Hold |
10,660
| – | – | ﹤0.01% | 70 |
|
|
2015
Q2 | $7K | Sell |
10,660
-25
| -0.2% | -$17 | ﹤0.01% | 64 |
|
|
2015
Q1 | $7K | Hold |
10,685
| – | – | ﹤0.01% | 64 |
|
|
2014
Q4 | $8K | Hold |
10,685
| – | – | ﹤0.01% | 63 |
|
|
2014
Q3 | $5K | Hold |
10,685
| – | – | ﹤0.01% | 64 |
|
|
2014
Q2 | $5K | Sell |
10,685
-150
| -1% | -$73 | ﹤0.01% | 61 |
|
|
2014
Q1 | $3K | Buy |
10,835
+375
| +4% | +$139 | ﹤0.01% | 63 |
|
|
2013
Q4 | $4K | Hold |
10,460
| – | – | ﹤0.01% | 63 |
|
|
2013
Q3 | $21K | Hold |
10,460
| – | – | 0.01% | 60 |
|
|
2013
Q2 | $21K | Buy |
+10,460
| New | +$18.4K | 0.01% | 59 |
|
Dillon & Associates's GCVRZ Position: Q1 2020 in Review
Dillon & Associates sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 10,260 shares — an estimated $9K sold.
Dillon & Associates first reported a position in GCVRZ in Q2 2013 and held it in 27 quarters. The position peaked at $21K in Q3 2013. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Dillon & Associates reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Dillon & Associates sold 10,260 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $9K.
- Dillon & Associates first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 27 quarters.
- Dillon & Associates's Sanofi Contingent Value Rights position peaked at $21K in Q3 2013.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Dillon & Associates's 13F filing for Q1 2020, filed 7 May 2020.